GDNF family receptor alpha-2 (GFRA2) (GFRA2)

GDNF family receptor alpha-2 (GFRA2) is a glycosylphosphatidylinositol (GPI)-anchored cell surface receptor that belongs to the glial cell line-derived neurotrophic factor (GDNF) receptor family [2, 3]. It serves as the preferential receptor for neurturin (NRTN) and can also bind GDNF with lower affinity [6, 9]. Upon ligand binding, GFRA2 forms a signaling complex with the RET receptor tyrosine kinase, triggering RET autophosphorylation and activating downstream pathways such as MAPK and PI3K/Akt [6, 12]. These signaling events are essential for the survival, differentiation, and maintenance of specific neuronal populations, particularly parasympathetic and sensory neurons [1, 4]. In addition to its role in neural development, GFRA2 is implicated in various pathological conditions, including chronic pain, itch, and several types of cancer where its overexpression correlates with poor prognosis [6, 10, 11]. Therapeutic strategies targeting GFRA2 include the use of neurotrophic factor ligands for neuroregeneration and the development of small-molecule inhibitors to disrupt the GFRα-RET interface for treating pain and pruritus [11]. Preclinical studies have shown that GFRA2 deficiency leads to innervation deficits in the gut and impaired glandular secretion, highlighting potential safety considerations for systemic inhibition [1, 4].

Other names

GDNFRBRETL2TRNR2NTNRANeurturin receptor alphaGDNF receptor betaGFR-alpha-2GDNFR-alpha-2RET ligand 2

Agonism: Binding of ligands like Neurturin (NRTN) or GDNF to GFRA2 facilitates the recruitment and autophosphorylation of the RET receptor tyrosine kinase, activating downstream MAPK and PI3K/Akt signaling pathways [6, 9]. Antagonism: Small-molecule inhibitors disrupt the formation of the ligand-RET-GFRA2 complex, thereby preventing RET activation and downstream signaling [11].